TD Cowen Maintains Outperform on NeoGenomics, Lowers Price Target to $19
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Dan Brennan has maintained an Outperform rating on NeoGenomics (NASDAQ:NEO) but has lowered the price target from $22 to $19.

December 29, 2023 | 1:40 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
TD Cowen analyst Dan Brennan reaffirms an Outperform rating on NeoGenomics but reduces the price target from $22 to $19.
The reduction in price target by TD Cowen, despite maintaining an Outperform rating, could lead to a negative short-term sentiment among investors, as it suggests a lower expected future stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100